Quintet Private Bank Europe S.A. Reduces Holdings in BioNTech SE (NASDAQ:BNTX)

Quintet Private Bank Europe S.A. lessened its holdings in BioNTech SE (NASDAQ:BNTXFree Report) by 53.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 385 shares of the company’s stock after selling 440 shares during the period. Quintet Private Bank Europe S.A.’s holdings in BioNTech were worth $40,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Neuberger Berman Group LLC acquired a new stake in shares of BioNTech during the 4th quarter worth about $1,562,000. Truist Financial Corp acquired a new stake in shares of BioNTech during the fourth quarter worth $1,445,000. Fifth Third Bancorp grew its position in shares of BioNTech by 3,881.3% in the fourth quarter. Fifth Third Bancorp now owns 16,642 shares of the company’s stock valued at $1,756,000 after purchasing an additional 16,224 shares during the period. Bamco Inc. NY increased its stake in BioNTech by 123.1% in the third quarter. Bamco Inc. NY now owns 158,911 shares of the company’s stock valued at $17,264,000 after purchasing an additional 87,686 shares during the last quarter. Finally, US Bancorp DE lifted its position in BioNTech by 420.7% during the fourth quarter. US Bancorp DE now owns 28,614 shares of the company’s stock worth $3,020,000 after buying an additional 23,119 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

BNTX traded down $3.92 during midday trading on Friday, reaching $92.08. 768,301 shares of the company’s stock were exchanged, compared to its average volume of 984,847. The firm has a market capitalization of $21.89 billion, a price-to-earnings ratio of 184.16 and a beta of 0.27. The business has a 50-day simple moving average of $92.78 and a two-hundred day simple moving average of $95.83. BioNTech SE has a one year low of $85.21 and a one year high of $125.83. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTXGet Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million during the quarter, compared to analyst estimates of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. As a group, research analysts predict that BioNTech SE will post -2.11 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $113.00 target price on shares of BioNTech in a report on Monday, June 10th. TD Cowen boosted their price objective on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. Evercore ISI initiated coverage on shares of BioNTech in a report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 price objective on the stock. Finally, BMO Capital Markets decreased their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, BioNTech presently has a consensus rating of “Hold” and an average target price of $111.70.

Get Our Latest Research Report on BioNTech

BioNTech Company Profile

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Articles

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXFree Report).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.